

# Introduction to diagnostic test accuracy network meta-analysis

**Prof. Areti-Angeliki Veroniki**

*St. Michael's Hospital, Unity Health Toronto*

*Institute of Health Policy, Management and Evaluation, University of Toronto*

**Dr. Sofia Tsokani**

*Methods Support Unit, Cochrane Central Executive Team*

*School of Medicine, Aristotle University of Thessaloniki, Greece*

Trusted evidence.  
Informed decisions.  
Better health.

November 20<sup>th</sup>, 2024



# Outline

1. Introduce Diagnostic Test Accuracy (DTA) Studies
2. Discuss about process of conducting a systematic review with DTA meta-analysis
3. Present how to build the network geometry of DTA studies
4. Extend DTA meta-analysis methods to DTA network meta-analysis methods (DTA-NMA)
5. Identify potential implications in DTA-NMA



# Poll Question 1

**Which of the following best describes your role?**

- Editor of systematic reviews
- User of systematic reviews
- Systematic reviewer
- Statistician
- Methodologist
- Other

Trusted evidence.  
Informed decisions.  
Better health.

## Poll Question 2

### **What is your familiarity with Meta-Analysis of Diagnostic Test Accuracy studies?**

- I know about it and have used it.
- I am aware of it, but have not applied it before.
- I have no idea what it is.

# Diagnostic Test Accuracy studies

- **Diagnostic Tests** are used to ascertain whether an individual **has** or **not** a disease
- Most tests are imperfect, errors will occur - **not** always **accurate**
- ‘**Reference standard**’ is a **test** that can be used to estimate the accuracy of the imperfect tests
- **Binary outcome**: positive / negative test result

Statistical methods usually focus on **two quantities** characterizing the accuracy of a test: **sensitivity** and **specificity**

What proportion of those **with** the disease does the test detect?  
(**sensitivity, SENS**)





What proportion of those **without** the disease does the test get right?  
(**specificity, SPEC**)

		Disease	
		⊕	⊖
Test	⊕	TP	FP
	⊖	FN	TN
		Sensitivity = $TP / (TP + FN)$	Specificity = $TN / (TN + FP)$

# Thresholds

- Binary markers (X-rays)
- Continuous markers (blood tests)
  - Require setting cut-off values (thresholds)
  - Trade-off between sensitivity and specificity

There is a **trade-off** between sensitivity and specificity as the threshold is set in **different points!**




# Threshold effect

- The same threshold can imply different SENS and SPEC in different groups
- A solution can be to perform Meta-Analysis at each threshold separately or a subset of thresholds

## BUT...

- Restricting to a common threshold **reduces data**
- The common threshold **may not be** the threshold a reader wants to know about



# Example: The anatomy of a DTA research question



Rapid Antigen Test A for diagnosis of COVID-19 in asymptomatic adults

Index test

Target Condition

Population

Reference Standard

PCR



# Example: 2x2 table

Index test: Rapid Antigen test A for COVID-19

Reference Standard: RT-PCR

		Reference standard Result		Total
		Positive (D+)	Negative (D-)	
Index Test Result	Positive (T+)	TP= <b>27</b>	FP= <b>2</b>	Positive Test Results = <b>29</b>
	Negative (T-)	FN= <b>3</b>	TN= <b>98</b>	Negative Test Results = <b>101</b>
	Total	Diseased= <b>30</b>	Non-Diseased= <b>100</b>	Sample size = <b>130</b>

- Sensitivity, Specificity (**90%**, **98%**)
- Test identified 90% of COVID-19 diseased and 98% of non-diseased individuals

# Steps of a Systematic Review of DTA studies



1. Define the question
2. Define objectives and eligibility criteria
3. Develop protocol
4. Search for studies
5. Study selection and Data collection
6. Assess bias and applicability
7. Analyze and present results
8. Interpret results and draw conclusions

## Review Question

What is the diagnostic accuracy of rapid antigen and rapid molecular tests for the diagnosis of the SARS-CoV-2 infection in adults and children according to the reference standard PCR test?

### Population

Adults and/  
or children  
screened/  
suspected for  
COVID-19

### Index Test(s)

COVID-19 rapid lateral  
flow antigen tests and  
rapid molecular tests  
(with result in  $\leq 1$ h)  
Ref Std: PCR test

### Target Condition

SARS-CoV-2  
infection

**Reference  
standard:** PCR

# Intervention vs DTA reviews

## Intervention Reviews

### Components of Intervention review research question (PICO)

- P opulation
- I nterventions
- C omparators
- O utcomes
- S tudy design



## Diagnostic Test Accuracy (DTA) Reviews

### Components of Intervention review research question (PIT)

- P opulation
- I ndex Test(s)
- T arget Condition
  - Reference Standard
- S tudy design



# Steps of a Systematic Review of DTA studies



1. Define the question
2. Define objectives and eligibility criteria
3. Develop protocol
4. Search for studies
5. Study selection and Data collection
6. Assess bias and applicability
7. Analyze and present results
8. Interpret results and draw conclusions

## Objectives of the review

### Primary objective

To assess the diagnostic accuracy of rapid antigen and rapid molecular tests for the diagnosis of the SARS-CoV-2 infection in adults and children

### Secondary objectives


To assess the accuracy of clinical assessment in SARS-CoV-2 infection :

- according to sample type (e.g., saliva, nasal swab)
- In symptomatic and asymptomatic participants

# Steps of a Systematic Review of DTA studies

<https://training.cochrane.org/handbook>


- ❑ PICOS(T) framework, developed using PRISMA-P
- ❑ Register with PROSPERO (and publish in open access journal)



- Deeks JJ et al. *Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0.* Cochrane. 2023
- McInnes MDF et al. *Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement.* JAMA. 2018
- Whiting PF et al. *QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies.* Ann Intern, 2011
- Yang B et al. *QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies.* Ann Intern Med. 2021

# Meta-analysis

## 10 studies exploring accuracy of Test A for Covid-19



- ✓ Summarize information
- ✓ Synthesis of information from individual studies, addressing the same research question
- ✓ Statistically combine study-results to obtain summary estimates

# The generic meta-analysis process

1. Calculation of an **overall summary** (average) of **high precision**, coherent with all observed data
2. Typically a “**weighted average**” is used where more informative (**larger**) studies have more say
3. Assess the degree to which the study results **deviate** from the overall summary
4. Investigate possible **explanations** for the deviations

What is **SO critical** that we have to consider in meta-analyses?

**Test threshold!!!**

- Accuracy varies with **index test threshold**
- Can we average **over test thresholds**?
- How would we **interpret** the result?
- *Thresholds can be important for both index and reference tests*



# The generic meta-analysis process

## Challenges for DTA reviews

- There are **two summary statistics** for each study: **SENS** and **SPEC**
- **Threshold effects** induce **correlations** between **SENS** and **SPEC**
  - Often thresholds vary between studies
- Heterogeneity is the norm - **substantial variation** in sensitivity and specificity
  - Different groups can have different sensitivities and specificities at the **same threshold**

## Pooling sensitivity and specificity *separately*?

- Ignores threshold as source of heterogeneity
- Is biased towards studies with high sensitivity or specificity
  - Pooled estimates of sensitivity and specificity may be biased towards 1 or 0, depending on study results





# Multiple studies – Single index test


- Systematic review evaluating a single index test:
  - Aims to evaluate a diagnostic test vs. a reference standard
- How does test accuracy **vary** with clinical & methodological **characteristics**?
- The outcome is to model the test results (binary outcome: positive / negative test result) – assess the **diagnostic accuracy** of a **single test**

## **Bivariate model**

- Single threshold
- Summary point

## **HSROC model**

- Multiple thresholds
- Summary curve



# Multiple Diagnostic Tests vs. Multiple Interventions

- Diagnostic tests are usually compared in **the same subjects** within a study
  - Correlated observations – the NMA methods should account for this correlation structure
  - Should estimate sensitivity & specificity: bivariate model
- Interventions are compared between **independent groups** (different groups of patients)
  - Use effect measures (OR, RR, RD) to compare effectiveness among treatments

		Interventions	Diagnostic tests
	Aim	Compare two treatments	Discriminate two groups
Pairwise meta-analysis	Groups	2 interventions	With/without target condition
	Outcome	Event yes/no	Test positive/negative
	Proportions	$r_1, r_0$	Sens, 1 – Spec
	Effect measures	RD = $r_1 - r_0$	$J = \text{Sens} + \text{Spec} - 1$
		OR = $\frac{r_1(1-r_0)}{r_0(1-r_1)}$	DOR = $\frac{\text{Sens*Spec}}{(1-\text{Sens})(1-\text{Spec})}$
Multivariate pairwise meta-analysis	Modeling	Univariate model, contrast-based	Bivariate model, arm-based
	Groups	2 interventions	With/without target condition
	Outcome	$K \geq 2$ outcomes	$K \geq 2$ tests
	Measures	Pairs of proportions $(r_{1k}, r_{0k}), k = 1, \dots, K$	Pairs of accuracy measures $(\text{Sens}_k, 1 - \text{Spec}_k), k = 1, \dots, K$
	Effect measures	RD $_k, k = 1, \dots, K$ OR $_k, k = 1, \dots, K$	$J_k, k = 1, \dots, K$ DOR $_k, k = 1, \dots, K$
	Modeling	Multi(K)variate model	Multi(2K)variate model


RD = risk difference; OR = odds ratio; DOR = diagnostic odds ratio; J = Youden index.

Rücker G. Springer, Cham. 2018

# Network of interventions

All interventions and the control group are depicted in the network plot


Studies compare at least 2 interventions (2-arm, 3-arm, etc.)



Study ID	Type of study	Intervention comparisons
1	2-arm	B vs C
2	3-arm	A vs B vs C
3	2-arm	A vs C
4	2-arm	B vs Control
5	2-arm	A vs B
6	2-arm	A vs B
7	2-arm	B vs Control

# Network of diagnostic tests

Reference standard (RS) is not considered in the network but as a **bridge** for comparing index tests.  
 Index test vs RS: single-test study




Study ID	Type of study	Data	Test comparisons	Edges/Circles in the network
1	Single-test	Test D vs RS	Test D vs. RS	Circle for test D
2	Paired-test	Test B vs RS Test C vs RS	Test B vs. Test C	Dashed line connecting tests B and C
3	Triple-test	Test A vs RS Test B vs RS Test C vs RS	Test A vs. Test B Test A vs. Test C Test B vs. Test C	Closed triangle with solid line connecting tests A, B, and C
4	Paired-test	Test B vs RS Test D vs RS	Test B vs. Test D	Dashed line connecting tests B and D
5	Single-test	Test C vs RS	Test C vs. Reference	Circle for test C
6	Paired-test	Test A vs RS Test D vs RS	Test A vs. Test D	Dashed line connecting tests A and D
7	Paired-test	Test C vs RS Test D vs RS	Test C vs. Test D	Dashed line connecting tests C and D

# Scoping Review of DTA-NMA methods

# Scoping Review

- Search of PubMed, Web of Science, Scopus databases up until the 3rd March 2021
- Methodological and application papers comparing the accuracy of at least three index tests using:
  - hierarchical meta-regression models
  - models developed specifically for DTA-NMA



# DTA-NMA in the literature

**Table 1.** Properties of 13 diagnostic test accuracy (DTA) comparative meta-analysis methods

	Format of data tables required <sup>a</sup>	Arm-based model	Can model imperfect reference standards	Can model multiple thresholds	Type of studies that can be modelled	Bayesian setting	Accounts for correlation between tests	Models more than two index tests	Software
Bivariate meta-regression [21]	2 × 2	Yes	No	No	Any	No	No	Yes	R ( <i>CopulaDTA</i> [24], <i>lme4</i> [25], <i>mada</i> [26], <i>meta4diag</i> [27], <i>Metatron</i> [28], <i>Mvmeta</i> [29]), Stata ( <i>meqrlogit</i> [30])
HSROC meta-regression [22]	2 × 2	Yes	No	Yes <sup>d</sup>	Any	No	No	Yes	OpenBUGS/ WinBUGS [31] R ( <i>NMADiagT</i> [32])
Trikalinos 2014 [5]	Joint classification	Yes	No	No	Single- / Paired-test	Yes	Yes	No <sup>b</sup>	R ( <i>rjags</i> [33])
Menten-Lesaffre 2015 [4]	2 × 2	No	Yes <sup>c</sup>	No	Paired- / Multiple-test	Yes	No	Yes	OpenBUGS/ WinBUGS [31]
Dimou 2016 [3]	Joint classification	Yes	No	No	Single- / Paired-test	No	Yes	No <sup>b</sup>	Stata ( <i>mvmeta</i> [34])
Cheng 2016 [Model A] [8]	Joint classification	Yes	No	No	Any	Yes	No	Yes	R ( <i>R2jags</i> [35])
Cheng 2016 [Model B] [8]	Joint classification	Yes	No	Yes <sup>d</sup>	Any	Yes	No	Yes	R ( <i>R2jags</i> [35])
Cheng 2016 [Model C] [8]	Joint classification	Yes	No	No	Any	Yes	Yes	Yes	R ( <i>R2jags</i> [35])
Nyaga (ANOVA) 2018 [2]	2 × 2	Yes	No	No	Any	Yes	Yes	Yes	Stan ( <i>rstan</i> [36],[37] in R)
Nyaga (beta-binomial) 2018 [38]	2 × 2	Yes	No	No	Any	Yes	Yes	Yes	Stan ( <i>rstan</i> [36],[37] in R)
Ma 2018 [9] <sup>e</sup>	Joint classification	Yes	Yes	No	Any	Yes	Yes	Yes	OpenBUGS/ WinBUGS [31], R ( <i>NMADiagT</i> [45])
Owen 2018 [39]	2 × 2	Yes	No	Yes	Any	Yes	Yes	Yes	OpenBUGS/ WinBUGS [31]
Lian 2019 [40]	Joint classification	Yes	Yes	Yes <sup>d</sup>	Any	Yes	Yes	Yes	Stan ( <i>rstan</i> [36],[37] in R), R ( <i>NMADiagT</i> [45])

Abbreviations: DOR, diagnostic odds ratio; SE, standard error; DTA, diagnostic test accuracy; NMA, network meta-analysis; HSROC, hierarchical summary receiver operating characteristic.

<sup>a</sup> 2 × 2 data includes the number of true positives, true negatives, false positives and false negatives.

Most popular

- Properties of DTA-NMA models differ and may influence interpretation and decision-making

## DTA-NMAs:

- ‘Borrow strength’ across studies by simultaneously analysing multiple DTA studies
- Account for between-study correlations between sensitivity and specificity induced through threshold effects

# Joint classification tables

Index test: Rapid Antigen test A, Rapid Antigen test B for COVID-19

Reference Standard: RT-PCR

		Reference standard Result		Total
		Positive (D+)	Negative (D-)	
Index Test A Result	Positive (T+)	TP= 27	FP= 2	Positive Test Results = 29
	Negative (T-)	FN= 3	TN= 98	Negative Test Results = 101
	Total	Diseased= 30	Non-Diseased= 100	Sample size = 130



		Reference standard Result		Total
		Positive (D+)	Negative (D-)	
Index Test B Result	Positive (T+)	TP= 17	FP= 9	Positive Test Results = 26
	Negative (T-)	FN= 13	TN= 91	Negative Test Results = 104
	Total	Diseased= 30	Non-Diseased= 100	Sample size = 130

		Index Test A Result		Total
		Positive (D+)	Negative (D-)	
Index Test B Result	Positive (T+)	TP= 20	FP= 10	Positive Test Results = 30
	Negative (T-)	FN= 10	TN= 90	Negative Test Results = 100
	Total	Diseased= 30	Non-Diseased= 100	Sample size = 130

*Individual Participant Data required*



# Application Papers



- Majority employed bivariate/HSROC meta-regression models
- 2x2 tables were available for 32 networks
  - 8 of these reported data at multiple thresholds per study

# DTA-NMA in the literature

**Table 1.** Properties of 13 diagnostic test accuracy (DTA) comparative meta-analysis methods

	Format of data tables required <sup>a</sup>	Arm-based model	Can model imperfect reference standards	Can model multiple thresholds	Type of studies that can be modelled	Bayesian setting	Accounts for correlation between tests	Models more than two index tests	Software
Bivariate meta-regression [21]	2 × 2	Yes	No	No	Any	No	No	Yes	R ( <i>CopulaDTA</i> [24], <i>lme4</i> [25], <i>mada</i> [26], <i>meta4diag</i> [27], <i>Metatron</i> [28], <i>Mvmeta</i> [29]), Stata ( <i>meqrlogit</i> [30])
HSROC meta-regression [22]	2 × 2	Yes	No	Yes <sup>d</sup>	Any	No	No	Yes	OpenBUGS/ WinBUGS [31]R( <i>NMADiagT</i> [32])
Trikalinos 2014 [5]	Joint classification	Yes	No	No	Single- / Paired-test	Yes	Yes	No <sup>b</sup>	R ( <i>rjags</i> [33])
Menten-Lesaffre 2015 [4]	2 × 2	No	Yes <sup>c</sup>	No	Paired- / Multiple-test	Yes	No	Yes	OpenBUGS/ WinBUGS [31]
Dimou 2016 [3]	Joint classification	Yes	No	No	Single- / Paired-test	No	Yes	No <sup>b</sup>	Stata ( <i>mvmeta</i> [34])
Cheng 2016 [Model A] [8]	Joint classification	Yes	No	No	Any	Yes	No	Yes	R ( <i>R2jags</i> [35])
Cheng 2016 [Model B] [8]	Joint classification	Yes	No	Yes <sup>d</sup>	Any	Yes	No	Yes	R ( <i>R2jags</i> [35])
Cheng 2016 [Model C] [8]	Joint classification	Yes	No	No	Any	Yes	Yes	Yes	R ( <i>R2jags</i> [35])
Nyaga (ANOVA) 2018 [2]	2 × 2	Yes	No	No	Any	Yes	Yes	Yes	Stan ( <i>rstan</i> [36],[37] in R)
Nyaga (beta-binomial) 2018 [38]	2 × 2	Yes	No	No	Any	Yes	Yes	Yes	Stan ( <i>rstan</i> [36],[37] in R)
Ma 2018 [9] <sup>e</sup>	Joint classification	Yes	Yes	No	Any	Yes	Yes	Yes	OpenBUGS/ WinBUGS [31], R ( <i>NMADiagT</i> [45])
Owen 2018 [39]	2 × 2	Yes	No	Yes	Any	Yes	Yes	Yes	OpenBUGS/ WinBUGS [31]
Lian 2019 [40]	Joint classification	Yes	Yes	Yes <sup>d</sup>	Any	Yes	Yes	Yes	Stan ( <i>rstan</i> [36],[37] in R), R ( <i>NMADiagT</i> [45])

*Abbreviations:* DOR, diagnostic odds ratio; SE, standard error; DTA, diagnostic test accuracy; NMA, network meta-analysis; HSROC, hierarchical summary receiver operating characteristic.  
<sup>a</sup> 2 × 2 data includes the number of true positives, true negatives, false positives and false negatives.

# DTA-NMA in the literature

## Bivariate meta-regression model

*Reitsma et al. (2005)*

- A **covariate** for **test type** is used to explore sensitivity and specificity between tests
- **Assumes** that participants undergoing different tests are **independent subgroups** within each study
- Does **not account** for the within-study correlation between tests within study

## ANOVA model

*Nyaga et al. (2018)*

- A **two-stage hierarchical** model based on a two-way ANOVA model
- **Allow for correlations** between tests within study

## Beta-binomial model

*Nyaga et al. (2018)*

- Sensitivity & specificity are directly modelled using a **beta-binomial** defined in  $[0,1]$
- **Allow for correlations** between tests within study

## Hierarchical Latent Class model

*Menten and Lesaffre (2015)*



- Based on differences (contrasts) between the different tests in the network
- Allows for **imperfect reference standards**
- **Correlations between tests** from the same study are **ignored**

## Variance component model

*Owen et al. (2018)*

- Allows for considering **multiple thresholds**
- Incorporates **constraints on threshold effects**

# Empirical assessment of the DTA-NMA methods



- Nyaga beta-binomial model estimated lower between study heterogeneity for both sensitivity and specificity
- Owen *et al.* model showed that different test thresholds included, may cause differences in results

# In summary...

- Bivariate/HSROC meta-regression model:
  - It has been **widely used** over the years
  - Conservative approach and accessible to many review authors
  - **But**, it ignores the within-study correlation between tests - assumes observations are independent
- More **advanced** methods and models have been **developed**
  - Most account for correlations between tests within a study
- NMA methodology of **intervention** studies is **not** applicable to **DTA** studies
  - **Correlated observations** – tests are given to the same participants
  - Two effect sizes should be modelled (**sensitivity & specificity**) – pairs of accuracy measures should be modelled in multivariate models (2K-variate, with K tests).
  - **Network geometry** differs – single-test studies are presented (reference standard is not a node in the network)

# In summary...

- Software and Model Complexity
  - most of the detected models use **Bayesian** setting
  - **programming** challenges - code availability problems (including convergence issues)
  - **time-consuming** models (e.g., dataset with antigen COVID-19 tests required >48 hours to run the Nyaga ANOVA model)
- Datasets
  - within the same study different number of participants may receive the index tests of interest (i.e., **missing participant data** problem)
  - **correlations** between tests are **frequently not available** in the original DTA studies (i.e. the joint classification table is rarely provided in publications)

# In summary...

- There is **not** a **single valid method** for DTA-NMA analysis
  - **multiple factors** influence the choice of model (data availability, test thresholds, study designs, software familiarity)
  - **meta-regression** models **ignore** the **within-study correlation** between tests
  - selection between the methods **may impact** on the NMA results, especially for **specificity**
- Some models require **joint classification tables**
  - **individual participant data** would make this information available
  - **rarely reported** in DTA studies
  - **difficulties** in their **availability-data sharing**

# DTA-NMA Example

More than a year ago Health Canada and the Public Health Agency of Canada commissioned the team to **conduct a review to determine the most sensitive and/or specific rapid test for the diagnosis of COVID-19**



Veroniki et al. *BMC Medicine* (2023) 21:110  
<https://doi.org/10.1186/s12916-023-02810-0>

BMC Medicine

REVIEW


Open Access




## Rapid antigen-based and rapid molecular tests for the detection of SARS-CoV-2: a rapid review with network meta-analysis of diagnostic test accuracy studies

Areti Angeliki Veroniki<sup>1,2\*</sup>, Andrea C. Tricco<sup>1,3,4</sup>, Jennifer Watt<sup>1</sup>, Sofia Tsokani<sup>5</sup>, Paul A. Khan<sup>1</sup>, Charlene Soobiah<sup>1,2</sup>, Ahmed Negm<sup>6</sup>, Amanda Doherty-Kirby<sup>7</sup>, Paul Taylor<sup>7</sup>, Carole Lunny<sup>1</sup>, Jessie McGowan<sup>8</sup>, Julian Little<sup>8</sup>, Patrick Mallon<sup>9</sup>, David Moher<sup>10</sup>, Sabrina Wong<sup>11</sup>, Jacqueline Dinnes<sup>12</sup>, Yemisi Takwoingi<sup>12</sup>, Lynora Saxinger<sup>6</sup>, Adrienne Chan<sup>13</sup>, Wanrudee Isaranuwatchai<sup>14</sup>, Bryn Lander<sup>15</sup>, Adrienne Meyers<sup>16</sup>, Guillaume Poliquin<sup>16</sup> and Sharon E. Straus<sup>1,2,17</sup>

Network plot for rapid antigen tests  
68 studies, 104,961 participants, 36 tests



Network plot for rapid molecular tests  
27 studies, 10,449 participants, 23 tests



We set up our team considering to include the policy-makers who requested the evidence, at least one clinician/content expert, two patient partners, content experts, research methodologists, and statisticians.



# Research Question



## Research question and eligibility criteria

- **Population:** Adults and/or children screened/suspected for COVID-19
- **Index tests:** We included studies evaluating one or more commercially available COVID-19 **rapid lateral flow antigen test** or **rapid molecular test** (providing a result in  $\leq 1$  hour) used for screening of asymptomatic individuals or the diagnosis of COVID-19 infection in symptomatic individuals
- **Target condition:** COVID-19 infection
  - **Reference Standard:** polymerase chain reaction (PCR) test
- **Study design:** We included RCTs and observational studies, providing the 2x2 table data
- **Outcome:** Sensitivity and specificity of rapid antigen and molecular tests suitable for screening and diagnosing COVID-19

*Registered protocol with PROSPERO: CRD42021289712*


# Data analysis

- Limited to basic descriptive summary of studies
  - Country of conduct and type of rapid test
- Kept the analysis high-level:
  - Random-effects DTA meta-analysis (bivariate model)
  - Random-effects DTA-NMA (Nyaga ANOVA model)
- Estimated sensitivity and specificity for each test along with their 95% credible intervals
- Investigated potential sources of heterogeneity that may influence diagnostic accuracy using:
  - **Subgroup analysis:** symptom status (asymptomatic vs symptomatic), sample type (e.g., saliva, nasal swab), participant type (e.g., general public, healthcare worker), and rapid molecular test category (i.e., rRT-PCR, PT-Isothermal, RT-Lamp)
  - **Meta-regression:** age
- Assessed transitivity based on the distribution of the above potential effect modifiers across test comparisons




# Report Findings

- Used reporting guidelines to ensure transparent and complete reporting of our research approach and findings (e.g., PRISMA-DTA and PRISMA-NMA Checklist)

**Network plot for rapid antigen tests**  
68 studies, 104,961 participants, 36 tests



**Network plot for rapid molecular tests**  
27 studies, 10,449 participants, 23 tests




# Summarized results


## DTA-NMA results



### Rapid antigen tests



### Rapid molecular tests



# Report Findings



- Used reporting guidelines to ensure transparent and complete reporting of our research approach and findings (e.g., PRISMA-DTA and PRISMA-NMA Checklist)

## Summarized results from the bivariate DTA meta-analysis model

Type	Test	# Studies (# patients)	Summary estimates		Heterogeneity standard deviation	
			Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity	Specificity
Rapid molecular test	Xpert Xpress	5 (763)	0.98 (0.94, 1.00)	0.98 (0.94, 0.99)	0.79	0.53
Rapid antigen test	Standard Q COVID-19 Ag	13 (8740)	0.72 (0.53, 0.86)	0.99 (0.98, 1.00)	1.49	1.82
	PanBio COVID-19 Ag Rapid test (Abbott)	16 (32,151)	0.72 (0.61, 0.81)	0.99 (0.99, 1.00)	0.98	1.72
	SARS-CoV-2 Rapid Antigen Test (Roche)	7 (6065)	0.77 (0.55, 0.90)	0.99 (0.96, 1.00)	1.33	1.52
	Standard F COVID-19 Ag	5 (6428)	0.65 (0.50, 0.78)	0.98 (0.97, 0.99)	0.67	0.41

# There is still a lot to explore!

- Explore which **factors impact** on the **performance** of the DTA-NMA methods
- Extend the **ranking metrics** for **multiple outcomes** to DTA-NMA methods
- **DTA-NMA assumptions:** Appropriate methods are needed to explore the consistency assumption in DTA-NMA accounting for both sensitivity and specificity
- New methods are necessary to deal with and account for different study designs in a DTA-NMA

# Acknowledgements

Ridhi Agarwal · Eirini Pagkalidou · Gerta Rücker · Dimitris Mavridis · Yemisi Takwoingi

## Diagnostic test accuracy network meta-analysis methods: A scoping review and empirical assessment

[Areti Angeliki Veroniki](#)<sup>a,b,1</sup>   · [Sofia Tsokani](#)<sup>c,1</sup> · [Ridhi Agarwal](#)<sup>d</sup> · [Eirini Pagkalidou](#)<sup>e</sup> · [Gerta Rücker](#)<sup>f</sup> · [Dimitris Mavridis](#)<sup>c,g</sup> · [Yemisi Takwoingi](#)<sup>d,h</sup> [Show less](#)

[Affiliations & Notes](#)  [Article Info](#) 

- a Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, 209 Victoria Street, East Building, Toronto, Ontario M5B 1T8, Canada
- b Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
- c Department of Primary Education, School of Education, University of Ioannina, Ioannina, Greece
- d Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK
- e Department of Hygiene, Social-Preventive Medicine and Medical Statistics, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
- f Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center – University of Freiburg, Stefan-Meier-Strasse 26, 79104 Freiburg, Germany
- g Paris Descartes University, Sorbonne Paris Cité, Faculté de Médecine, Paris, France
- h NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
- 1 joint first authors: Areti Angeliki Veroniki, MSc, PhD Sofia Tsokani, MSc.



WILEY

ENABLING DISCOVERY | POWERING EDUCATION | SHAPING WORKFORCES


## Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy

Jonathan J. Deeks, Patrick M. Bossuyt, Mariska M. Leeflang, Yemisi Takwoingi

ISBN: 978-1-119-75618-7

E-Book | June 2023 | 432 Pages

A guide to conducting systematic reviews of test accuracy



Use promo code **COC20** for 20% at [wiley.com](http://wiley.com) expires 01/01/2025


## Cochrane Handbook for Systematic Reviews of Interventions, 2nd Edition

Julian P. T. Higgins, James Thomas, Jacqueline Chandler, Miranda Cumpston, Tianjing Li, Matthew J. Page, Vivian A. Welch

ISBN: 978-1-119-53665-9

E-Book | September 2019 | 736 pages

The revised edition of the Handbook offers the only guide on how to conduct, report and maintain a Cochrane Review



Use promo code **COC20** for 20% at [wiley.com](http://wiley.com) expires 01/01/2025

WILEY

# A guide to conducting systematic reviews of test accuracy

Cochrane

## Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy

Edited by  
Jonathan J. Deeks  
Patrick M. Bossuyt  
Mariska M. Leeflang  
Yemisi Takwoingi

WILEY Blackwell

Use code  
**COC20** for  
20% off

Cochrane



**THANK YOU**



[a.veroniki@utoronto.ca](mailto:a.veroniki@utoronto.ca)



[stsokani@cochrane.org](mailto:stsokani@cochrane.org)